These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 11215675)
1. Mammary tumor induction and premature ovarian failure in ApcMin mice are not enhanced by Brca2 deficiency. Bennett LM; McAllister KA; Ward T; Malphurs J; Collins NK; Seely JC; Davis BJ; Wiseman RW Toxicol Pathol; 2001; 29(1):117-25. PubMed ID: 11215675 [TBL] [Abstract][Full Text] [Related]
2. Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice. Karabinis ME; Larson D; Barlow C; Wynshaw-Boris A; Moser AR Carcinogenesis; 2001 Feb; 22(2):343-6. PubMed ID: 11181458 [TBL] [Abstract][Full Text] [Related]
3. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Moser AR; Mattes EM; Dove WF; Lindstrom MJ; Haag JD; Gould MN Proc Natl Acad Sci U S A; 1993 Oct; 90(19):8977-81. PubMed ID: 8415640 [TBL] [Abstract][Full Text] [Related]
4. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Ludwig T; Fisher P; Murty V; Efstratiadis A Oncogene; 2001 Jul; 20(30):3937-48. PubMed ID: 11494122 [TBL] [Abstract][Full Text] [Related]
5. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Bennett LM; McAllister KA; Malphurs J; Ward T; Collins NK; Seely JC; Gowen LC; Koller BH; Davis BJ; Wiseman RW Cancer Res; 2000 Jul; 60(13):3461-9. PubMed ID: 10910057 [TBL] [Abstract][Full Text] [Related]
6. Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice. Moser AR; Hegge LF; Cardiff RD Cancer Res; 2001 Apr; 61(8):3480-5. PubMed ID: 11309311 [TBL] [Abstract][Full Text] [Related]
7. The APC I1307K allele and BRCA-associated ovarian cancer risk. Maresco DL; Arnold PH; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Boyd J Am J Hum Genet; 1999 Apr; 64(4):1228-30. PubMed ID: 10090911 [No Abstract] [Full Text] [Related]
8. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Ludwig T; Chapman DL; Papaioannou VE; Efstratiadis A Genes Dev; 1997 May; 11(10):1226-41. PubMed ID: 9171368 [TBL] [Abstract][Full Text] [Related]
9. N-Ethyl-N-nitrosourea induces mammary cancers in the pituitary-isografted mouse which are histologically and genotypically distinct from those induced by N-methyl-N-nitrosourea. Swanson SM; Guzman RC; Tsukamoto T; Huang TT; Dougherty CD; Nandi S Cancer Lett; 1996 Apr; 102(1-2):159-65. PubMed ID: 8603364 [TBL] [Abstract][Full Text] [Related]
10. The ROSA26 LacZ-neo(R) insertion confers resistance to mammary tumors in Apc(Min/+) mice. Kohlhepp RL; Hegge LF; Moser AR Mamm Genome; 2001 Aug; 12(8):606-11. PubMed ID: 11471054 [TBL] [Abstract][Full Text] [Related]
11. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Teng DH; Bogden R; Mitchell J; Baumgard M; Bell R; Berry S; Davis T; Ha PC; Kehrer R; Jammulapati S; Chen Q; Offit K; Skolnick MH; Tavtigian SV; Jhanwar S; Swedlund B; Wong AK; Kamb A Nat Genet; 1996 Jun; 13(2):241-4. PubMed ID: 8640236 [TBL] [Abstract][Full Text] [Related]
12. Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Rajan JV; Marquis ST; Gardner HP; Chodosh LA Dev Biol; 1997 Apr; 184(2):385-401. PubMed ID: 9133444 [TBL] [Abstract][Full Text] [Related]
13. A delayed chemically induced tumorigenesis in Brca2 mutant mice. Yan DH; Wen Y; Su LK; Xia W; Wang SC; Zhang S; Gan L; Lee DF; Spohn B; Frey JA; Hortobagyi GN; Hung MC Oncogene; 2004 Mar; 23(10):1896-901. PubMed ID: 14981540 [TBL] [Abstract][Full Text] [Related]
14. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Moynahan ME Oncogene; 2002 Dec; 21(58):8994-9007. PubMed ID: 12483515 [TBL] [Abstract][Full Text] [Related]
15. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424 [TBL] [Abstract][Full Text] [Related]
16. Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice. Zhuang SM; Wiseman RW; Söderkvist P Oncogene; 2002 Aug; 21(36):5643-8. PubMed ID: 12165863 [TBL] [Abstract][Full Text] [Related]
17. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459 [TBL] [Abstract][Full Text] [Related]
18. Mutations in Apc and p53 synergize to promote mammary neoplasia. Méniel V; Hay T; Douglas-Jones A; Sansom OJ; Clarke AR Cancer Res; 2005 Jan; 65(2):410-6. PubMed ID: 15695381 [TBL] [Abstract][Full Text] [Related]
19. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Healey CS; Dunning AM; Teare MD; Chase D; Parker L; Burn J; Chang-Claude J; Mannermaa A; Kataja V; Huntsman DG; Pharoah PD; Luben RN; Easton DF; Ponder BA Nat Genet; 2000 Nov; 26(3):362-4. PubMed ID: 11062481 [TBL] [Abstract][Full Text] [Related]
20. Somatic mutational mechanisms involved in intestinal tumor formation in Min mice. Shoemaker AR; Luongo C; Moser AR; Marton LJ; Dove WF Cancer Res; 1997 May; 57(10):1999-2006. PubMed ID: 9157997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]